about
Comparative Usability Study of a Novel Auto-Injector and an Intranasal System for Naloxone Delivery.Non-fatal overdose in the 12 months following treatment for substance use disordersA quantitative and qualitative evaluation of the British Columbia Take Home Naloxone program.Overdose prevention and naloxone prescription for opioid users in San FranciscoPreventing opiate overdose deaths: examining objections to take-home naloxone.Risk factors for nonfatal overdose at Seattle-area syringe exchanges.Evaluation of a naloxone distribution and administration program in New York City.Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles, CA.Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study.Overdose prevention for injection drug users: lessons learned from naloxone training and distribution programs in New York City.Mortality among young injection drug users in San Francisco: a 10-year follow-up of the UFO study.Providing naloxone to substance users for secondary administration to reduce overdose mortality in New York CityAssociation between non-fatal opioid overdose and encounters with healthcare and criminal justice systems: Identifying opportunities for interventionOrienting patients to greater opioid safety: models of community pharmacy-based naloxone.Attitudes of Australian heroin users to peer distribution of naloxone for heroin overdose: perspectives on intranasal administrationFentanyl-associated fatalities among illicit drug users in Wayne County, Michigan (July 2005-May 2006)Evidenced-based treatment of opioid-dependent patients.Mortality among people who inject drugs: a systematic review and meta-analysis.Naloxone treatment in opioid addiction: the risks and benefits.A response to the opioid overdose epidemic: naloxone nasal sprayPitfalls of intranasal naloxone.Qualitative assessment of take-home naloxone program participant and law enforcement interactions in British Columbia.EMS runs for suspected opioid overdose: implications for surveillance and prevention.Naloxone Administration in US Emergency Departments, 2000-2011.Personal social network factors associated with overdose prevention training participationOverdoses are injuries tooTake-home emergency naloxone to prevent heroin overdose deaths after prison release: rationale and practicalities for the N-ALIVE randomized trial.Location of fatal prescription opioid-related deaths in 12 states, 2008-2010: Implications for prevention programs.No deaths associated with patient refusal of transport after naloxone-reversed opioid overdose.Reducing the harm of opioid overdose with the safe use of naloxone : a pharmacologic review.Identifying injection drug users at risk of nonfatal overdose.Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effects of changes to the chain linking of the C14-amino group to the aryl ring.Changing law from barrier to facilitator of opioid overdose prevention.Opioid harm reduction strategies: focus on expanded access to intranasal naloxone.Intravenous use of intranasal naloxone: A case of overdose reversal.Naloxone dosage for opioid reversal: current evidence and clinical implications.
P2860
Q30654725-1C4AC990-A20F-4408-90EF-618D225F34F8Q33636934-4F5E6C47-FF0A-4DFC-9532-A80A33BF1779Q34280151-A55CC98F-4D3E-4DC3-947F-C4902FF3F40BQ34420178-65945D8C-3B16-446D-A22E-003D5F66D87CQ34434452-C09B4EBA-7101-4322-9ED8-D23052FDC602Q34588009-7214D818-2418-44D6-BF84-F503E3E55075Q34788017-4E39CCAF-DA8A-491B-A91D-1E194C2722CBQ34923675-80641348-554D-43A7-B889-F240B7E644CFQ35135608-E16736DB-4206-4E90-B105-5D3B94580887Q35633605-173E7FD4-1554-432F-8A58-C41522DC0A4AQ35734357-4DCF3F26-99FC-4DFE-8E04-6FD62186A98BQ35741203-01175B8D-75B0-4F95-9346-81988BE2D1C1Q35882669-EA5CD305-1B32-459F-B725-3C0D6351E9DDQ35923351-260E703C-14A4-45E1-ACF3-3C330ACE8DD6Q36579537-ED3AAD00-85CE-4144-8D99-D4476686FA1DQ36621844-FAA76900-C802-440F-9C06-AC3827CFCB5FQ36628470-77F0D31D-348A-490B-8E4B-F51D02EFE0F8Q36706977-2497F9A7-875A-40A6-ACF7-809C1D66AEA0Q36762428-23B36AED-E537-481E-BBDF-DEF7DE7607ACQ36890018-EA570E55-73CA-43F6-911F-0EE5DDF81DDCQ36891449-39AF5AB2-A461-408C-8723-060E8E8E0878Q36923289-6EB143F3-7C83-43D3-A881-124322592C30Q36929678-97D47D51-3B3B-49F6-ABAE-A58AC798E43AQ36936494-C32D8615-1D81-4D23-A1FC-B0937C813096Q36974799-29226DDF-4DE7-4445-8D9D-49136C3E18D7Q37030077-618FEFDD-0B27-4D0A-B117-7876AB1A4898Q37225942-0065D9FC-F8DB-4E81-8AB7-2B9067592F2FQ37371933-36B30607-10F1-455D-A46D-4E0B4DBB928BQ37879686-9A04A9DF-3F05-4ACA-8E99-4FF4807D7A2FQ38417339-25BC0F24-7AC4-438E-8769-9CE255C81ABBQ39800119-902BC9CF-2CCC-45A6-AC45-169A27A96933Q40227077-A451367A-F0D6-40C1-B79D-0E9774C565E4Q42266033-22F7A131-240A-48E4-9921-8E244917E9C9Q44346905-DBD01A81-C6A0-4D9C-85A7-71F719A7A41DQ46695159-F8372F31-8712-488E-A085-7AC88D58003FQ48275689-A1865E80-3C84-4B43-8348-86D440DCCE57
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Take-home naloxone to reduce heroin death.
@ast
Take-home naloxone to reduce heroin death.
@en
type
label
Take-home naloxone to reduce heroin death.
@ast
Take-home naloxone to reduce heroin death.
@en
prefLabel
Take-home naloxone to reduce heroin death.
@ast
Take-home naloxone to reduce heroin death.
@en
P2860
P1433
P1476
Take-home naloxone to reduce heroin death.
@en
P2093
Catherine T Baca
Kenneth J Grant
P2860
P304
P356
10.1111/J.1360-0443.2005.01259.X
P407
P577
2005-12-01T00:00:00Z